Diabetes in Night Owls; ‘Paradigm-Shifting’ Drugs; Transgender Trials Unethical?

Compared with women who are early birds, night owls had a 19% higher risk of developing diabetes, after taking into account lifestyle and sociodemographic factors. (Annals of Internal Medicine)

“Although numerous public health strategies geared toward reducing or preventing pediatric obesity have been implemented, these have had limited success overall,” wrote researchers in a perspective on considering pediatric obesity a U.S. public health emergency. (Pediatrics)

A randomized trial showed that kids ages 4 to 6 had better weight trajectories over time if involved in an intensive parent-support obesity intervention. (International Journal of Obesity)

Over 75% of U.S. physicians said tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy) are “paradigm-shifting” for weight loss, but few were satisfied with cost and insurance coverage, according to a new survey. (InCrowd)

There’s a renewed push to get the government to cover infertility treatments for veterans and active-duty service members. (Axios)

Genetic mutations in the GLP-1 receptor likely modify the efficacy of GLP-1 receptor agonists. (Nature Metabolism)

Randomized trials for transgender medicine are ethically problematic, researchers say. (STAT)

Exposures to certain phenols, parabens, and per- and poly-fluoroalkyl substances were linked with increased odds of previous melanoma and ovarian cancer diagnoses. (Journal of Exposure Science & Environmental Epidemiology)

Artificial intelligence and machine learning provided a high diagnostic and classification performance in detecting polycystic ovarian syndrome (PCOS). (Frontiers in Endocrinology)

And in related news, following the keto diet may help reduce testosterone levels in women with PCOS. (Journal of the Endocrine Society)

Please enable JavaScript to view the

comments powered by Disqus.